Indivior (NASDAQ:INDV – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of $0.32 per share and revenue of $259.30 million for the quarter.
Indivior Trading Up 0.7 %
Shares of NASDAQ INDV opened at $10.91 on Thursday. The stock has a market capitalization of $1.50 billion, a PE ratio of -272.63 and a beta of 0.73. The stock’s fifty day simple moving average is $11.56 and its two-hundred day simple moving average is $10.89. Indivior has a 12-month low of $7.33 and a 12-month high of $23.22.
Wall Street Analyst Weigh In
INDV has been the topic of several recent research reports. Piper Sandler reaffirmed an “overweight” rating and set a $16.00 target price (up previously from $15.00) on shares of Indivior in a research report on Friday, October 25th. RODMAN&RENSHAW raised Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw initiated coverage on Indivior in a research report on Tuesday, January 28th. They set a “buy” rating and a $16.00 target price on the stock.
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Stories
- Five stocks we like better than Indivior
- Investing in the High PE Growth Stocks
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- What is an Earnings Surprise?
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.